« Back
Home /
Pefloxacin (mesylate)

Pefloxacin (mesylate)

Item no.	HY-B0147A-10mM
Manufacturer	MedChem Express
CASRN	70458-95-6
Amount	10 mM/1 mL
Quantity options	100 mg 10 g 10 mM/1 mL 1 g 500 mg 5 g
Category	Food Safety Antibiotics Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.73
Citations	[1]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92.\|[2]Hussy P, et al. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073-8.\|[3]Clarke AM, et al. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams. J Antimicrob Chemother. 1985 Jan;15(1):39-44.\|[4]Jones BM, et al. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. J Antimicrob Chemother. 1986 Jun;17(6):739-46.\|[5]Tabary X, et al. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I. Antimicrob Agents Chemother. 1987 Dec;31(12):1925-8.\|[6]Fantin B, et al. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother. 1991 Jul;35(7):1413-22.\|[7]Sun YW, et al. Pefloxacin and ciprofloxacin increase UVA-induced edema and immune suppression. Photodermatol Photoimmunol Photomed. 2001 Aug;17(4):172-7.\|[8]Truffot-Pernot C, et al. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle. 1991 Mar;72(1):57-64.\|[9]Salmon D, et al. Activities of pefloxacin and ciprofloxacin against experimental malaria in mice. Antimicrob Agents Chemother. 1990 Dec;34(12):2327-30. Xenobiotica. 2021 Apr;51(4):479-493. Chemosphere. 2019 Jun:225:378-387.
Smiles	O=C(C1=CN(CC)C2=C(C=C(F)C(N3CCN(C)CC3)=C2)C1=O)O.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Pefloxacinium mesylate
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Antibiotic; Bacterial; DNA/RNA Synthesis; Parasite; Topoisomerase
Manufacturer - HS Code	H302, H315, H320, H335
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	429.46
Product Description	Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies[1][2][3][4][5][6][7][8][9].
Manufacturer - Research Area	Infection; Inflammation/Immunology
Solubility	DMSO : 12.5 mg/mL (ultrasonic)\|H2O : ≥ 100 mg/mL
Manufacturer - Pathway	Anti-infection; Cell Cycle/DNA Damage
Clinical information	Launched
Isoform	Quinolone
UNSPSC Code	12352005
Precautionary	H302, H315, H320, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.